STRM.BIO is developing a non-viral, cell-derived delivery platform for safe, targeted, and scalable in vivo delivery of genetic medicines, initially focused on rare hematological diseases such as Fanconi anemia and in vivo CAR-T therapies.

STRM.BIO is developing a non-viral, cell-derived delivery platform for safe, targeted, and scalable in vivo delivery of genetic medicines, initially focused on rare hematological diseases such as Fanconi anemia and in vivo CAR-T therapies.